AGTC to Present at Upcoming Scientific Conferences

GAINESVILLE, Fla. and CAMBRIDGE, Mass., April 19, 2016 -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced participation in two upcoming scientific conferences.

• World Orphan Drug Congress – Washington, D.C. (April 20-22)
  Eric Olson, Senior Director, Corporate Development will give a presentation entitled “A novel AAV-based gene therapy platform for the treatment of rare diseases” at 4:00pm EDT on Thursday, April 21 during which he will discuss AGTC’s proprietary gene therapy platform.

• Retinal Cell and Gene Therapy Innovation Summit – Seattle, Wash. (April 28-29)
  Jeff Chulay, M.D., DTM&H, Vice President and Chief Medical Officer, will lead a session about AGTC’s clinical development programs on Thursday, April 28 entitled “Development of AAV Gene Therapy Vectors for Achromatopsia and X-Linked Retinitis Pigmentosa.”

About AGTC

AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC's lead product candidates are designed to treat inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function, and which currently lack effective medical treatments.

AGTC's product pipeline includes six named ophthalmology development programs across five targets (X-linked retinoschisis, X-linked retinitis pigmentosa, achromatopsia, wet age-related macular degeneration and blue cone monochromacy), two non-ophthalmology programs (alpha-1 antitrypsin deficiency and adrenoleukodystrophy) and early research studies in additional indications.  AGTC employs a highly targeted approach to selecting and designing its product candidates, choosing to develop therapies for indications having high unmet medical need, clinical feasibility and commercial potential. AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as expertise in the formulation, manufacture and physical delivery of gene therapy products.

IR/PR CONTACTS:
David Carey (IR) or Danielle Lewis (PR)
Lazar Partners Ltd.
T: (212) 867-1768 or (212) 843-0211
[email protected] or [email protected]

CORPORATE CONTACTS:
Larry Bullock
Chief Financial Officer
Applied Genetic Technologies Corporation
T: (386) 462-2204
[email protected]

Stephen Potter
Chief Business Officer
Applied Genetic Technologies Corporation
T: (617) 413-2754
[email protected]